The FDA approval of Samsung Bioepis’ high-concentration, citrate-free formulation of Hadlima, a biosimilar referencing Humira (adalimumab), is the first high-concentration adalimumab biosimilar to be approved in the United States.
Hadlima, 1 of 7 FDA-approved biosimilars referencing Humira (adalimumab), now will be offered in a high-concentration, citrate-free (100 mg/mL) version, as the FDA had granted the new formulation regulatory approval.
The low-concentration (50 mg/mL) formulation of Hadlima (adalimumab-bwwd) was originally approved in July 2019, and both formulations will launch in July 2023. Hadlima is also available in the European Union under the name Imraldi.
Until January 2023, Humira will not face any biosimilar competition because biosimilar manufacturers have made settlement agreements with AbbVie, the maker of Humira, to postpone launches. In July 2023, between 5 and 7 adalimumab biosimilars are expected to launch on the US market.
Adalimumab products are used to treat several rheumatic conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis or axial spondyloarthritis, Crohn disease, and ulcerative colitis.
“With this approval, we now have both a low- and high-concentration adalimumab biosimilar approved by the FDA, marking an important step towards expanding treatment options for patients suffering from certain chronic, autoimmune diseases…. By leveraging our development expertise, manufacturing excellence, and supply chain reliability, we will continue our work to ensure health care systems have more affordable treatment options available,” said Byoungin Jung, vice president and regulatory affairs team leader at Samsung Bioepis, in a statement.
Currently in the United States, the high-concentration version of Humira represents about 80% of total adalimumab prescriptions. The new formulation of Hadlima is the first high-concentration adalimumab biosimilar to be approved in the United States. Hadlima will be offered to patients in a prefilled syringe or autoinjector.
Hadlima was developed as part of a commercialization agreement between Samsung Bioepis, the manufacturer, and Organon, a spinoff company of Merck that will be in charge of commercialization in the United States. Organon also commercializes 4 other Samsung Bioepis biosimilars in several global markets: infliximab (Renflexis), etanercept (Brenzys, Eticovo), bevacizumab (Aybintio), and trastuzumab (Ontruzant).
“Based on our success commercializing our adalimumab biosimilar in other markets around the world, combined with our established presence in the biosimilar space, we are excited about the opportunity to launch Hadlima in the US in 2023…. Today, adalimumab is the largest drug expense in the US. We look forward to making our biosimilar available for those that rely on it to help manage their disease,” said Joe Azzinaro, vice president and global commercial lead biosimilars at Organon.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.